CAMBRIDGE, Mass., July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
More representative trial populations and standardized subgroup reporting are needed in non–small cell lung cancer (NSCLC) research, according to a meta-analysis published in Cancers, which found no ...
Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...
CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive ...
(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...
Lumateperone met the primary endpoint achieving a statistically significant and clinically meaningful reduction in MADRS total score at week 6 vs placebo. Treatment with lumateperone, an atypical ...
SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late ...
Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- ...
Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback